Loading...

Targovax

DB:TA5
Snowflake Description

Flawless balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
TA5
DB
NOK419M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Targovax ASA, a clinical stage immuno-oncology company, engages in the development of targeted immunotherapies for cancer patients. The last earnings update was 11 days ago. More info.


Add to Portfolio Compare Print
  • Targovax has significant price volatility in the past 3 months.
TA5 Share Price and Events
7 Day Returns
6.6%
DB:TA5
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
-
DB:TA5
-10.2%
DE Biotechs
-6%
DE Market
TA5 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Targovax (TA5) 6.6% -39.7% - - - -
DE Biotechs -2.4% 1.8% -7.7% -10.2% 51.2% 10.1%
DE Market 1.8% 4.2% 7.4% -6% 10.1% 15.4%
1 Year Return vs Industry and Market
  • No trading data on TA5.
  • No trading data on TA5.
Price Volatility
TA5
Industry
5yr Volatility vs Market

Value

 Is Targovax undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Targovax. This is due to cash flow or dividend data being unavailable. The share price is €0.675.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Targovax's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Targovax's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:TA5 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in NOK NOK-2.79
OB:TRVX Share Price ** OB (2019-04-18) in NOK NOK6.64
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 422 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Targovax.

DB:TA5 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OB:TRVX Share Price ÷ EPS (both in NOK)

= 6.64 ÷ -2.79

-2.38x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Targovax is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Targovax is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Targovax's expected growth come at a high price?
Raw Data
DB:TA5 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.38x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
26.1%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Targovax, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Targovax's assets?
Raw Data
DB:TA5 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in NOK NOK7.12
OB:TRVX Share Price * OB (2019-04-18) in NOK NOK6.64
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.84x
DB:TA5 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OB:TRVX Share Price ÷ Book Value per Share (both in NOK)

= 6.64 ÷ 7.12

0.93x

* Primary Listing of Targovax.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Targovax is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Targovax's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Targovax has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Targovax expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
26.1%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Targovax expected to grow at an attractive rate?
  • Unable to compare Targovax's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Targovax's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Targovax's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:TA5 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:TA5 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 26.1%
DB:TA5 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 89.2%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.5%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:TA5 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in NOK Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:TA5 Future Estimates Data
Date (Data in NOK Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 96 -39 -39 1
2020-12-31 43 -107 -122 1
2019-12-31 0 -164 -152 2
DB:TA5 Past Financials Data
Date (Data in NOK Millions) Revenue Cash Flow Net Income *
2018-12-31 0 -112 -147
2018-09-30 0 -111 -139
2018-06-30 0 -108 -132
2018-03-31 0 -112 -129
2017-12-31 0 -107 -122
2017-09-30 0 -106 -121
2017-06-30 0 -102 -119
2017-03-31 0 -104 -118
2016-12-31 0 -109 -122
2016-09-30 0 -120 -134
2016-06-30 0 -129 -137
2016-03-31 0 -105 -117

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Targovax is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Targovax's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:TA5 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Targovax Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:TA5 Future Estimates Data
Date (Data in NOK Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31 -0.74 -0.74 -0.74 1.00
2020-12-31 -2.32 -2.03 -2.61 2.00
2019-12-31 -2.89 -2.66 -3.12 2.00
DB:TA5 Past Financials Data
Date (Data in NOK Millions) EPS *
2018-12-31 -2.79
2018-09-30 -2.64
2018-06-30 -2.52
2018-03-31 -2.59
2017-12-31 -2.58
2017-09-30 -2.72
2017-06-30 -2.82
2017-03-31 -3.09
2016-12-31 -3.55
2016-09-30 -4.37
2016-06-30 -5.10
2016-03-31 -5.18

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Targovax will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Targovax's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Targovax has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Targovax performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Targovax's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Targovax does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Targovax's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Targovax's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Targovax's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Targovax Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:TA5 Past Revenue, Cash Flow and Net Income Data
Date (Data in NOK Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 0.03 -147.02 61.06
2018-09-30 0.03 -138.75 59.57
2018-06-30 0.04 -132.39 59.51
2018-03-31 0.04 -129.28 57.27
2017-12-31 0.04 -121.95 52.71
2017-09-30 0.04 -121.40 52.96
2017-06-30 0.05 -118.87 51.75
2017-03-31 0.04 -118.38 51.49
2016-12-31 0.04 -122.45 53.58
2016-09-30 0.04 -134.11 53.24
2016-06-30 0.15 -137.22 56.18
2016-03-31 0.15 -116.52 47.60
2015-12-31 0.15 -91.82 37.38
2015-09-30 0.16 -56.50 23.12
2015-06-30 0.02 -31.87 10.87
2015-03-31 0.04 -21.74 7.83
2014-12-31 0.07 -17.65 5.91
2014-09-30 -2.84 -12.10 2.08
2014-06-30 -1.12 -9.72 2.28
2014-03-31 -0.37 -8.68 2.62
2013-12-31 0.36 -7.60 2.60

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Targovax has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Targovax has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Targovax improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Targovax's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Targovax has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Targovax's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Targovax's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Targovax is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Targovax's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Targovax's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 3.1x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Targovax Company Filings, last reported 3 months ago.

DB:TA5 Past Debt and Equity Data
Date (Data in NOK Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 374.70 53.06 154.89
2018-09-30 399.93 49.58 173.22
2018-06-30 433.99 48.92 200.70
2018-03-31 470.94 48.70 229.19
2017-12-31 507.16 48.81 265.29
2017-09-30 524.54 45.81 285.77
2017-06-30 359.42 45.71 115.82
2017-03-31 378.43 42.96 147.50
2016-12-31 401.17 39.71 171.63
2016-09-30 431.00 38.97 192.50
2016-06-30 356.90 38.24 107.25
2016-03-31 389.23 38.00 140.89
2015-12-31 422.87 38.11 173.90
2015-09-30 437.49 37.88 206.69
2015-06-30 42.62 0.00 44.47
2015-03-31 54.52 0.00 54.19
2014-12-31 60.67 0.00 62.55
2014-09-30 69.11 0.00 69.01
2014-06-30 73.17 0.00 72.24
2014-03-31
2013-12-31 0.28 9.93 8.37
  • Targovax's level of debt (14.2%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (1454.2% vs 14.2% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Targovax has sufficient cash runway for 1.4 years based on current free cash flow.
  • Targovax has sufficient cash runway for 1.4 years if free cash flow continues to grow at historical rates of 2% each year.
X
Financial health checks
We assess Targovax's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Targovax has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Targovax's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Targovax dividends. Estimated to be 0% next year.
If you bought €2,000 of Targovax shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Targovax's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Targovax's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:TA5 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:TA5 Future Dividends Estimate Data
Date (Data in NOK) Dividend per Share (annual) Avg. No. Analysts
2021-12-31
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Targovax has not reported any payouts.
  • Unable to verify if Targovax's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Targovax's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Targovax has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Targovax's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Targovax's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Targovax afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Targovax has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Targovax's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Øystein Soug
COMPENSATION NOK2,805,000
AGE 49
TENURE AS CEO 2.4 years
CEO Bio

Mr. Oystein Soug, M.Sc has been the Chief Executive Officer of Targovax ASA since November 1, 2016. Mr. Soug has 17 years' experience in international finance and corporate development and has been based primarily in Russia and Norway. He served as Chief Financial Officer of Targovax ASA from June 1, 2015 until October 2016. He served as the Chief Financial Officer of Algeta ASA(Orkla Group) since June 1, 2008 and builds up the functions of Finance, IR, Compliance, IT and HR. Mr. Soug served as the Chief Financial Officer of SladCo (Orkla Foods CIS) and Project Manager in Orkla's Corporate Development M&A team at Norwegian Orkla group. He joined the Orkla Group in 2002. Prior to Orkla Group, Mr. Soug co-founded and managed Webmercs and he spent nearly six years in banking with European Bank for Reconstruction and Development (in Russia), Credit Suisse (China) and Dresdner Bank (Germany). He served as Vice Chairman and Director of Bionor Pharma ASA since May 15, 2013 until March 19, 2016. Mr. Soug has an MSc in Economics and Finance, a Master of International Management (CEMS) and a BA in Business, all from the University of St Gallen in Switzerland.

CEO Compensation
  • Øystein's compensation has increased whilst company is loss making.
  • Øystein's remuneration is about average for companies of similar size in Germany.
Management Team Tenure

Average tenure of the Targovax management team in years:

3.1
Average Tenure
  • The tenure for the Targovax management team is about average.
Management Team

Øystein Soug

TITLE
Chief Executive Officer
COMPENSATION
NOK3M
AGE
49
TENURE
2.4 yrs

Berit Iversen

TITLE
VP & Head of CMC
COMPENSATION
NOK2M

Magnus Jäderberg

TITLE
Chief Medical Officer
COMPENSATION
NOK3M
TENURE
3.8 yrs

Erik Wiklund

TITLE
Chief Business Officer
COMPENSATION
NOK942K
TENURE
0.6 yrs

Anne-Kirsti Aksnes

TITLE
Vice President of Clinical Development
COMPENSATION
NOK1M
TENURE
4.3 yrs

Tina Madsen

TITLE
Vice President of Quality Assurance
COMPENSATION
NOK1M
TENURE
4.3 yrs

Peter Skorpil

TITLE
Vice President of Business Development
COMPENSATION
NOK1M
TENURE
4 yrs

Jon Eriksen

TITLE
Special Advisor
COMPENSATION
NOK2M
TENURE
1.3 yrs

Torbjørn Furuseth

TITLE
Chief Financial Officer
TENURE
0.6 yrs

Gustav Gaudernack

TITLE
Chief Scientific Adviser
Board of Directors Tenure

Average tenure and age of the Targovax board of directors in years:

3.7
Average Tenure
59
Average Age
  • The tenure for the Targovax board of directors is about average.
Board of Directors

Patrick Vink

TITLE
Chairman of the Board
TENURE
1.4 yrs

Per Anders Samuelsson

TITLE
Director
COMPENSATION
NOK200K
AGE
57
TENURE
3.8 yrs

Bente-Lill Romøren

TITLE
Director
COMPENSATION
NOK133K
TENURE
6.9 yrs

Eva-Lotta Allan Coulter

TITLE
Non-Executive Director
COMPENSATION
NOK133K
AGE
59
TENURE
3.6 yrs

Diane Mellett

TITLE
Non-Executive Director
AGE
57
TENURE
3.6 yrs

Johan Christenson

TITLE
Director
COMPENSATION
NOK200K
AGE
60
TENURE
3.8 yrs

Robert Burns

TITLE
Director
COMPENSATION
NOK774K
AGE
71
TENURE
3.8 yrs

Catherine Wheeler

TITLE
Director
TENURE
1 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
20. Jun 18 Buy Øystein Soug Individual 19. Jun 18 19. Jun 18 5,402 €1.26 €6,829
X
Management checks
We assess Targovax's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Targovax has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Targovax ASA, a clinical stage immuno-oncology company, engages in the development of targeted immunotherapies for cancer patients. It is developing a peptide-based targeted immunotherapy platform for patients with RAS-mutated cancers; and a virus-based oncolytic immunotherapy platform based on engineered oncolytic viruses armed with potent immune-stimulating transgenes for patients with solid tumors. The company’s product candidates include TG01, which is in Phase I/II clinical trial for the treatment of patients with resected adenocarcinoma of the pancreas; TG02 that is in Phase Ib exploratory trial for the treatment of colorectal cancer; and ONCOS-102 that is in Phase I/II study for the treatment of mesothelioma, ovarian cancer, colorectal cancer, and advanced prostate cancer. The company has clinical collaboration agreements with the Parker Institute for Cancer Immunotherapy and Cancer Research Institute. Targovax ASA is based in Oslo, Norway.

Details
Name: Targovax ASA
TA5
Exchange: DB
Founded:
NOK43,815,178
63,138,421
Website: http://www.targovax.com
Address: Targovax ASA
Lilleakerveien 2 C,
Oslo,
Oslo, 0283,
Norway
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OB TRVX Ordinary Shares Oslo Bors NO NOK 17. Jun 2014
DB TA5 Ordinary Shares Deutsche Boerse AG DE EUR 17. Jun 2014
LSE 0RIS Ordinary Shares London Stock Exchange GB NOK 17. Jun 2014
BATS-CHIXE TRVXO Ordinary Shares BATS 'Chi-X Europe' GB NOK 17. Jun 2014
Number of employees
Current staff
Staff numbers
26
Targovax employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/20 22:21
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/03/28
Last earnings filing: 2019/04/09
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.